Abstract. Growth-regulated oncogene · (GRO·) is a chemokine that plays a role not only in inflammation, but also in tumorigenesis. Accumulating data suggest that GRO· is involved in tumor development and invasion in various malignancies, such as melanoma and bladder cancer. However, the pathophysiological role of GRO· in human colorectal cancers (CRCs) is still unknown. We examined the expression of GRO· and its pathophysiological significance in human CRCs and investigated whether GRO· promotes the invasive potential of colon cancer cells. Specimens of 62 primary CRCs were examined immunohistochemically for GRO·, and the relationship between GRO· expression and clinicopathological features was investigated. The mRNA expression of GRO· and its receptor CXCR2 was examined in ten colon cancer cell lines using RT-PCR. The effect of GRO· protein on invasive potential was investigated in DLD-1 and LoVo cells using a Matrigel invasion chamber assay. Forty-nine (79%) of the 62 CRCs showed positive immunoreactivity for GRO·. GRO· expression was significantly associated with tumor size, tumor stage, depth of invasion, LN metastasis and patient survival (P=0.021, P<0.0001, P=0.0033, P<0.0001, P=0.039, respectively). Expression of CXCR2 mRNA was detectable in all ten colon cancer cell lines examined, whereas expression of GRO· mRNA was detectable in six. Treatment with GRO· protein significantly increased the number of invasive cells. In conclusion, GRO· may play a pivotal role in the invasion of human CRCs.
Introduction
Chemokines are a group of small molecular cytokines that regulate the chemotaxis of leukocytes into inflammatory tissue (1) . They are classified into four groups (CXC, CC, C and CX 3 C) based on the arrangement of the two N-terminal cysteine residues (2, 3) . Chemokines play crucial roles in the regulation of inflammation, wound healing, and development (4) (5) (6) . Recently, accumulating evidence has indicated that they play equally important roles in the proliferation, survival, and migration of tumor cells, suggesting their involvement in tumor development and invasion (7) (8) (9) .
Growth-regulated oncogene · (GRO·) was originally identified by subtractive hybridization between tumorigenic and non-tumorigenic Chinese hamster embryonic fibroblasts (10) . GRO· belongs to the CXC chemokine subfamily (CXC chemokine ligand 1) and promotes chemoattraction, wound healing and angiogenesis through the seven-transmembrane G-protein-coupled receptor CXCR2 (11) (12) (13) . GRO· protein has also been isolated from human melanoma cells (14, 15) , and reported to be up-regulated in various tumors, such as glioma (16) , and cancers of the breast (17) (18) (19) , ovary (20) , prostate (21, 22) and bladder (23) . In these tumors, GRO· is suggested to be involved in tumor development and invasion as a growth and anti-apoptotic factor, or as a mediator to promote tumor invasion. Although elevated expression of GRO· has been reported in a series of human tumors, the role of GRO· in human colorectal cancers (CRCs) is poorly understood. Recently, GRO· was identified as a distinctly overexpressed gene in human CRCs by microarray analyses (24) (25) (26) , suggesting that GRO· is involved in the pathophysiology of human CRCs. Moreover, Wang et al have reported that GRO· promotes the growth of colon cancer cells in a mouse xenograft tumor model (27) . In the present study, therefore, we examined the expression of GRO· and its pathophysiological significance in human CRCs, and investigated whether the GRO· protein regulates the invasive potential of colon cancer cells.
Materials and methods
Tissue specimens and histological examination. A total of 62 patients with CRC who underwent surgical resection at ONCOLOGY REPORTS 24: 1479 -1486 , 2010 GRO· promotes invasion of colorectal cancer cells HIDEO The resected specimens were fixed in 10% formalin solution and embedded in paraffin. Multiple hematoxylineosin-stained sections of all the lesions were examined. The following factors were determined for all patients and lesions: age, gender, tumor size, tumor location, tumor differentiation, tumor invasion, lymph node metastases, and tumor stage. Tumor differentiation and stage were determined according to the WHO and UICC criteria, respectively. All these clinicopathological features are summarized in Table I .
Immunohistochemical staining. Immunohistochemical staining for GRO· was performed as described previously (28, 29) . In brief, the sections (4 μm thick) were deparaffinised, rehydrated, placed in 0.01 M citrate buffer (pH 6.0), and treated by microwave heating for 40 min. The sections were then preincubated with 0.3% H 2 O 2 in methanol for 20 min at room temperature to quench endogenous peroxidase activity. Subsequently, the sections were immunostained using an Envison + System kit (Dako, Carpinteria, CA, USA), according to the manufacturer's instructions. The sections were incubated with 1% bovine serum albumin in phosphatebuffered saline and then incubated with anti-GRO· antibody (dilution 1:20; R&D Systems, Minneapolis, MN, USA) for 1 h at room temperature. Then, the sections were incubated with HRP-conjugated secondary antibody for 60 min. After washing with phosphate-buffered saline, the sections were incubated in 3,3'-diaminobenzidine tetrahydrochloride with 0.05% H 2 O 2 for 5 min and then counterstained with Carazzi's hematoxylin. To evaluate the immunoreactivity of GRO· protein, at least 500 tumor cells were counted in 5 different visual fields for each cancerous tissue sample. A specimen was considered positive for GRO· when >20% of the tumor cells were stained.
Cell culture. Human colon cancer cell lines Caco2, HT29, Colo320DM, WiDr, SW403, Colo201, Colo205, and LoVo were cultured in RPMI-1640 medium (Invitrogen, Grand Island, NY, USA) with 10% fetal bovine serum (Sigma, St. Louis, MO, USA). DLD-1 and SW48 were cultured in Dulbecco's modified Eagle's medium (DMEM, Invitrogen) with 10% fetal bovine serum. All cell lines were incubated in a humidified incubator at 37˚C with an atmosphere of 5% CO 2 .
RNA extraction and reverse transcription-polymerase chain reaction (RT-PCR).
Total RNA was isolated from colon cancer cell lines with TRIzol reagent (Invitrogen). Five micrograms of total RNA was reverse-transcribed using oligodT primer (Applied Biosystems, Branchburg, NJ, USA) and 200 U of Superscript™ II reverse transcriptase (Invitrogen) in a total volume of 20 μl. For the subsequent PCR, pairs of oligonucleotide primers for human GRO·, human CXCR2 (GRO· receptor), and human glyceraldehydes-3-phosphate dehydrogenase (GAPDH) were prepared. Human GRO·, 5'-CCGAAGTCATAGCCACACTCAA-3' (sense), 5'-TGT TGCAGGCTCCTCAGAAATA-3' (antisense); human CXCR2, 5'-ATTCTGGGCATCCTTCACAG-3' (sense), 5'-T GCACTTAGGCAGGAGGTCT-3' (antisense); human GAPDH, 5'-GGCTGCTTTTAACTCTGGTA-3' (sense), 5'-ATGCCAGTGAGCTTCCCGT-3' (antisense). RT-PCR was performed as described previously (29) . In brief, one microliter of RT product (cDNA) was amplified by PCR in a 50-μl reaction volume containing 40 pmol of the above sets Table I . Clinicopathological features of the patients with colorectal cancers. 
of primers, 1.25 U of Ampli-Taq DNA polymerase (Applied Biosystems), and the final PCR buffer: 20 mM Tris-HCl (pH 8.4), 50 mM KCl, 2.5 mM MgCl 2 , 10 mM dithiothreitol, and 1 mM dNTP. The PCR amplification was performed as follows: at 95˚C for 5 min once; 35 cycles at 94˚C for 1 min, at 60˚C for 45 sec, and at 72˚C for 1 min; then at 72˚C for 7 min.
Cell invasion assay. Cell invasion assay was performed using BioCoat Matrigel invasion chambers (BD Biosciences, Bedford, MA, USA) in accordance with the manufacturer's protocol. Briefly, DLD-1 (5x10 4 ) or LoVo cells (5x10 4 ) were seeded in the insert of the Matrigel-coated invasion chamber (24 wells, 8-μm pore size) filled with serumfree DMEM medium containing different concentrations of GRO· (0-100 ng/ml). Then, the cells were incubated with DMEM medium containing 10% FBS in the lower chamber at 37˚C in 5% CO 2 . To inhibit the effects of GRO·, anti-GRO· antibody (20 μg/ml) was also added to the upper chamber. After incubation for 36 h, non-invading cells were removed using a cotton swab and the cells that had invaded into the lower surface of the membrane were fixed with ethanol. The invading cells were then stained with hematoxylin and counted using a microscope in 5 different visual fields (magnification, x200).
Statistical analysis. The ¯2 test was performed to determine correlations among the various parameters, and Fisher's extract test was also used, as necessary. Age, tumor size and the number of invasive cells are expressed as mean ± SEM. Statistical differences between the two groups were assessed by the unpaired two-tailed t-test or by the Mann-Whitney U test when data were not parametric. Cumulative survival rate was evaluated by the Kaplan-Meier method and analyzed by log-rank test. A P-value of <0.05 was considered to indicate statistical significance.
Results

Expression of GRO· in normal colon and CRC tissue.
In normal colorectal mucosa adjacent to the tumor, immunoreactivity for GRO· was observed in the cytoplasm of a few epithelial cells in the basal portion of crypts (Fig. 1A) . In the CRC tissue samples, GRO· immunoreactivity was detected in the cytoplasm of cancer cells (Fig. 1B) . Forty-nine (79.0%) of the 62 CRCs were positive for GRO· expression. In the GRO·-positive CRCs, cytoplasmic staining for GRO· was often more intense at the invasive front (Fig. 1C) than in the superficial part of the tumor (Fig. 1D) . Moreover, GRO· immunoreactivity was detected in CRCs showing various types of differentiation, including poorly differentiated adenocarcinoma (Fig. 1E ) and mucinous adenocarcinoma (Fig. 1F) .
Relationship between GRO· expression and clinicopathological features in CRCs.
To clarify the pathophysiological significance of GRO· expression in human CRCs, the differences between the clinicopathological features of patients with GRO·-positive CRC and those with GRO·-negative CRC were investigated. As shown in Table II , with regard to tumor size, GRO·-positive CRCs were significantly larger than GRO-negative CRCs (P=0.021). Moreover, tumor stage, depth of invasion, and prevalence of lymphatic invasion, venous invasion, and LN metastasis were significantly higher in the former than in the latter (P<0.0001, P=0.0033, P=0.0005, P=0.0078, P<0.0001, respectively) (Table II) . Representative images of the invasive front (C) and superficial part (D) of CRC. GRO· immunoreactivity is also detectable in poorly differentiated adenocarcinoma (E) and mucinous adenocarcinoma (F). Scale bars, 100 μm.
However, none of the other parameters, gender, age, tumor location, or differentiation, had a significant relationship to GRO· expression.
Prognostic significance of GRO· expression in patients with
CRC. Log-rank statistics showed that venous invasion, LN metastasis and tumor stage were significant prognostic factors for overall survival of patients with CRC (P=0.041, P=0.0048, P<0.0001, respectively). No significant correlation was evident between prognosis and other clinicopathological features. To evaluate the prognostic significance of GRO· expression in patients with CRC, Kaplan-Meier curves were generated. As shown in Fig. 2 , patients with GRO·-positive CRC had significantly shorter overall survival than those with GRO·-negative CRC (P=0.039).
Expression of GRO· and CXCR2 mRNA in colon cancer cell lines. Expression of mRNA for GRO· and its receptor CXCR2 was examined in 10 colon cancer cell lines using the RT-PCR method. As shown in Fig. 3 , expression of GRO· mRNA was detected in 6 (60%) of 10 colon cancer cell lines examined. However, expression of GRO· mRNA was not detected in the 4 remaining cell lines, Caco2, SW48, DLD-1 and Colo320DM. On the other hand, expression of CXCR2 mRNA was detected in all 10 of the colon cancer cell lines examined (Fig. 3) .
Effect of GRO· protein on invasive potential in colon cancer cells.
To clarify the pathophysiological role of GRO· protein in CRCs, we next examined the invasion ability of colon cancer cells stimulated with GRO· protein using a Matrigel invasion assay. When DLD-1 cells were unstimulated, only a few invaded across the membrane during incubation for 36 h Table II . Comparison of the clinicopathological features between the GRO·-positive and GRO·-negative CRC patients. ------------------------------------------------ Figure 2 . Overall survival in relation to GRO· expression in patients with colorectal cancer. Kaplan-Meier survival curves were constructed, and the difference between the GRO·-positive (n=49) and GRO·-negative (n=13) groups was analyzed by log-rank test. ( Fig. 4A and E) . However, when the cells were stimulated with GRO· protein, the number that showed invasion increased significantly in a dose-dependent manner (Fig. 4A) . We then inhibited the function of GRO· protein with a neutralizing antibody. Treatment with GRO· protein (100 ng/ml) significantly increased the number of invasive DLD-1 cells, but this effect was decreased by the addition of anti-GRO· antibody ( Fig. 4B and E) . There was no significant difference in the number of invasive cells between non-stimulated cells and cells treated with anti GRO· antibody ( Fig. 4B and E) .
------------------------------------------------
We next examined the effect of GRO· protein on invasive potential in LoVo cells which endogenously express GRO· When LoVo cells were unstimulated, some cells invaded across the membrane during the incubation for 36 h. The number of invasive cells in unstimulated LoVo cells was more than that in unstimulated DLD-1 cells. When the LoVo cells were stimulated with GRO· protein, the number of invasive cells increased in a dose-dependent manner (Fig. 4C) . Treatment with GRO· protein (100 ng/ml) significantly increased the number of invasive LoVo cells, but this effect was abolished by the concomitant administration of anti-GRO· antibody (Fig. 4D) . Moreover, the inhibition of endogenous GRO· function with a neutralizing antibody in unstimulated LoVo cells led the reduction in number of invasive cells (Fig. 4D) .
Discussion
Chemokines and their receptors are implicated in leukocyte migration to inflammatory sites and angiogenesis in various inflammatory conditions (6, 30) . Besides their functions in inflammation, accumulating evidence suggests that they also play critical roles in tumor development, invasion and metastasis (7) . In support of this idea, our immunohistochemical analyses revealed that a considerable number of human CRCs indeed produce GRO·. Moreover, we demonstrated that all of the human colon cancer cell lines we tested expressed CXCR2 mRNA. Previously, CXCR2 expression has been reported to be elevated in human CRCs (27, 31) . Thus, although we did not examine the expression of CXCR2 in human CRC tissues in the present study, it appears reasonable to speculate that the GRO·/CXCR2 axis is involved in the pathophysiology of human CRCs.
The most important finding of this study was that GRO·-positive CRCs showed a significantly larger tumor size, a higher tumor stage and a higher frequency of LN metastasis. We also demonstrated that GRO· immunostaining was often more intense at the invasive front of CRCs and GRO· protein indeed promoted the invasive potential of colon cancer cells. Recently, GRO· protein has been reported to exert a trophic and anti-apoptotic effect on colon cancer cells (26) . Moreover, several studies have indicated that GRO· promotes the invasive potential of glioma cells (16) and bladder cancer cells (23) . These studies, together with our present data, suggest that GRO· is involved in the development and invasion of human CRCs, acting as a trophic and anti-apoptotic factor and also a potential factor mediating tumor invasion, in an autocrine/paracrine manner.
One issue of interest is the molecular mechanism by which GRO· promotes tumor invasion and metastasis in CRCs. During the process of tumor invasion and metastasis, tumor cells need to acquire the capability to degrade the extracellular matrix and promote neoangiogenesis (32, 33) . Accumulating evidence suggests that activation of matrix metalloproteinase (MMP) and the promotion of angiogenesis play pivotal roles in chemokine-related tumor invasion and metastasis (34, 35) . Using a mouse cancer model, Kitamura et al demonstrated that activation of MMP-2 and MMP-9 is involved in CCL9/CCR1-related invasion of colon cancer (36) . Moreover, in invasive breast cancers, the CXCL12/ CXCR4 axis has been shown to play important roles in tumor angiogenesis (37) . Recent reports have also indicated that GRO· promotes tumor invasion by enhancing the expression of MMP-2 in bladder cancer cells (23) and mediates prostaglandin-induced angiogenesis by accelerating endothelial migration and tube formation in CRC (27) . From these data, it can be speculated that, in human CRCs, GRO· protein play a role in tumor invasion and metastasis through activation of MMPs and promotion of angiogenesis, although further studies will be needed to test this hypothesis.
Importantly, activation of the chemokine-receptor axis in cancer tissues sometimes affects the prognosis of patients. Previous studies have indicated that activation of the CXCL12/ CXCR4 axis is a predictor of poor outcome in patients with various tumors, such as glioma (38) , melanoma (39) , and cancers of breast (40, 41) , lung (42) , and colon (43, 44) . In this context, it is noteworthy that patients with GRO·-positive CRCs showed a significantly worse outcome than those with GRO·-negative CRCs, suggesting that GRO· is not only a potential mediator of tumor invasion but also a significant prognostic marker in CRC patients. Recently, Yan and Chen have reported that mutant p53 binds to the promoter region of the GRO· gene and exerts its function by inducing GRO· expression in colon cancer cells (45) . Since mutation of p53 is suggested to be involved in the tumorigenesis of various tumors (46) , GRO· may play a crucial role in the presence of p53 mutation. In support of this idea, our present study showed that GRO· was up-regulated in a large proportion of human CRCs, and was related to tumor invasion, LN metastasis and subsequent poor outcome. Therefore, inhibition of GRO·/CXCR2 signaling on tumor cells may have the potential to prevent invasion and metastasis in a large number of human CRCs. The therapeutic efficacy of targeting chemokine-receptor signaling has been intensively studied in melanoma (47, 48) , breast (34, (49) (50) (51) , and colon cancer (52, 53) . Recently, Wang et al showed that abolishment of GRO· signaling using anti-GRO· neutralizing antibodies led to a reduction of colorectal xenograft tumor growth with decreased the formation of microvessels (27) . Moreover, Yamamoto et al have reported that blockade of the GRO·/CXCR2 axis decreased the frequency of liver metastasis from colon cancer (54) . Taken together, these data suggest that GRO·/CXCR2 targeting could be a potentially useful new strategy for the treatment of human CRC, although more extensive studies will be required.
In summary, we have demonstrated that GRO· is upregulated in a large proportion of human CRCs and closely associated with advanced tumor stage, LN metastasis and poor prognosis. We have also clarified that GRO· protein promotes the invasive potential of colon cancer cells. These findings suggest that GRO· plays a pivotal role in the invasiveness of human CRCs. Therefore, targeting of GRO· as a potential treatment for invasive human CRCs should be examined in future studies.
